,

Irbeloc Plus

Contains:

  • Amlodipine IP 5 mg – Dihydropyridine Calcium Channel Blocker (CCB)

  • Irbesartan IP 150 mg – Angiotensin II Receptor Blocker (ARB)
    Therapeutic Class: Antihypertensive (CCB + ARB combination)
    Schedule: Schedule H (Prescription drug)

Irbeloc Plus is a dual-action antihypertensive medication combining Amlodipine, a long-acting calcium channel blocker, with Irbesartan, an angiotensin II receptor blocker. This combination offers synergistic blood pressure reduction by addressing both vascular resistance and the renin–angiotensin–aldosterone system (RAAS):

  • Amlodipine causes vasodilation by inhibiting calcium influx in vascular smooth muscle.

  • Irbesartan blocks angiotensin II–induced vasoconstriction and aldosterone release.

The result is improved blood pressure control, vascular protection, and reduced cardiovascular risk with a favorable safety profile.

Usage of Irbeloc Plus

  • Treatment of essential hypertension, especially when monotherapy is inadequate

  • Stage 2 hypertension or moderate-to-severe cases requiring dual therapy

  • Suitable for:

    • Patients with high cardiovascular risk

    • Diabetics with early nephropathy

    • Patients with left ventricular hypertrophy or metabolic syndrome

  • First-line combination therapy in some cases, per updated international guidelines


Common Side Effects

  • Amlodipine-related:

    • Peripheral edema

    • Headache

    • Dizziness

    • Flushing or palpitations

  • Irbesartan-related:

    • Fatigue

    • Dizziness or light-headedness

    • Hyperkalemia (rare)

    • Gastrointestinal upset

Note: Combination reduces amlodipine-induced edema due to RAAS modulation by Irbesartan.


Precautions

  • Hepatic or renal impairment: Use cautiously and monitor function periodically

  • Heart failure or post-MI: Monitor BP and renal parameters regularly

  • Avoid in pregnancy – Category D

  • Use cautiously in elderly and volume-depleted patients (risk of hypotension)

  • Monitor serum potassium and creatinine in patients on RAAS-active agents


Drug Interactions

  • Other antihypertensives: Additive hypotensive effects

  • NSAIDs: May blunt antihypertensive effect and impair renal function

  • Potassium supplements or potassium-sparing diuretics: Risk of hyperkalemia

  • Simvastatin: Dose limitation recommended when combined with amlodipine

  • Lithium: Risk of lithium toxicity increased with ARBs


Dosage and Administration

  • Once daily, preferably at a fixed time

  • Can be taken with or without food

  • No need to adjust dose based on food intake

  • Titrate if BP goals are not met, or use higher strengths if available


Storage

  • Store in a cool, dry place, below 25°C

  • Protect from light and moisture


Patient Counselling Tips

  • Take the tablet daily, even when BP feels normal

  • Inform about potential dizziness or swelling in feet

  • Advise regular monitoring of BP, renal function, and electrolytes

  • Instruct to avoid NSAIDs and potassium-rich foods/supplements unless advised

  • Encourage healthy lifestyle: low-sodium diet, exercise, and smoking cessation

Review My Order

0

Subtotal